Status:
COMPLETED
A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Osteoporosis
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
This study assessed the safety, tolerability, and pharmacokinetics of single-dose odanacatib (MK0822) with and without food.
Eligibility Criteria
Inclusion
- Subject is in good health
- Subject is a male between the ages of 18 and 45 years or (for Part I only) a female 60 years or younger
- Female subject is postmenopausal
- Subject is within 20% of ideal body weight
- Subject is a nonsmoker
Exclusion
- Subject has multiple or severe allergies to food or medications
- Subject has a history of metabolic bone disease, kidney/bladder stones, or treatment with bisphosphonates
- Subject has any infections, including HIV
- Subject consumes excessive amounts of caffeine or alcohol
- Subject has donated blood or taken another investigational drug in the last month
- Subject has a history of any illness that may confound the results of the study or pose additional risk in administering the study drug
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00863590
Start Date
June 1 2004
End Date
August 1 2008
Last Update
August 19 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.